Investor Day - PCI 12 May 2011
An investor 'Teach-in' was held on the 12 May to give the opportunity to better understand the quality of the products held within the Professional and Commercial division (PCI). Particular focus was given to the methodology of generating high value, niche content over digital platforms and the way in which the IBI business is incorporating the numerous data sources to generate new innovative solutions for our customers.
The product lines which were presented were Informa Agra, Lloyds List & Lloyds List Intelligence and the Citeline suite of products for the Clinical Trials marketplace. These divisions were chosen specifically to represent the philosophy and performance of the businesses in the IBI division.
Agra - a relatively recent mover to deep digital data and this presentation exemplifies the way in which these transitions have been carried out. Lloyds List Intelligence – further down the line than Agra and carrying an enormous amount of data for the international maritime, freight and transport market this presentation shows how the exploitation of the data sets has enabled Informa to radically change the oldest daily newspaper in the world. Citeline – the suite of products discussed here were born in the digital age and have always been 100% digital and have focused, once again on high value, deep data. These product lines are discussed in this context with examples of how the digital model enables high value customer retention.
Peter Rigby | Informa | Introduction & overview of IFI |
|
|
Lindsey Roberts | CEO IBI | Introduction to IBI and the philosophy of the division | Part 1 Part 2 |
|
Dr Philip Smith | MD, Informa Agra | A view into the suite of products providing information to the Agri-Business Sector | Part 1 Part 2 |
|
Matthew Horsford | e-Media Director | Discussion around the development of Lloyds List and Lloyds List Intelligence online offerings | Part 1 Part 2 |
|
Q&A | Session 1 | Q&A Session for presentations above | Part 1 Part 2 |
|
Linda Blackerby | President, Citeline | A look into the Citeline suite of products designed for the Clinical Trials market | Part 1 Part 2 |
|
Lindsey Roberts | CEO IBI | Summary of the session | ||
Q&A | >Session 2 | Q&A Session | Part 1 Part 2 |
|
Peter Rigby | CEO Informa | >Wrap up of the Investor Day | ||
Adam Walker | Financial Director | Interim Management Statement Q&A | IMS |